National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 6527 [2024-01954]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 22 / Thursday, February 1, 2024 / Notices
disseminates, communicates, and
promotes information to protect
communities from adverse health
impacts from air pollution; and (15)
coordinates asthma- and air qualityrelated activities throughout CDC.
Lead Poisoning Prevention and
Surveillance Branch (CNCD) (1)
establishes, monitors, and evaluates
goals and objectives for a national
childhood lead poisoning prevention
program and blood lead surveillance
system for CDC; (2) develops and
implements an integrated national
program to eliminate childhood lead
poisoning through partnerships with
U.S. Department of Housing and Urban
Development, U.S. Environmental
Protection Agency, other federal
agencies, and national organizations; (3)
coordinates efforts of federal, state,
local, tribal and territorial agencies that
have programs related to childhood lead
exposure and prevention to achieve
national objectives and performance
standards related to eliminating
childhood lead poisoning; (4) supports
state, local, tribal and territorial health
agencies, and other stakeholders, in
planning, developing, and
implementing childhood lead poisoning
prevention programs and blood lead
surveillance systems; (5) collects,
analyzes, and disseminates data on
blood lead levels in U.S. children; (6)
develops, conducts, and evaluates
epidemiologic research on childhood
lead poisoning including risk factors,
geographic distribution, and trends; (7)
works collaboratively across, NCEH,
CDC and with external partners to build
capacity for science, innovation, and
translation research to accelerate
progress towards national lead
poisoning prevention goals; (8) develops
and implements, in concert with other
federal agencies, national organizations,
and other appropriate groups, a training
agenda for public health professionals
related to childhood lead poisoning
prevention and surveillance activities;
(9) administers the CDC/NCEH Federal
Advisory Committee relevant to lead
poisoning prevention; and (10)
coordinates lead poisoning prevention
and surveillance activities through the
Division, Center, and with other
components of CDC and external
stakeholders, as appropriate.
Emerging Environmental Hazards and
Health Effects Branch (CCNCE) (1)
promotes public health protection from
environmental hazards and exposures,
as well as environmental health
disasters—both natural and
technological—through education,
training, and information dissemination
to the general public as well as the
public health and clinician
VerDate Sep<11>2014
17:12 Jan 31, 2024
Jkt 262001
communities; (2) serves as the CDC lead
to prepare for and respond to natural,
nuclear/radiological, and chemical
emergencies; (3) provides CDC
leadership to protect public health and
safety through independent oversight of
the Army destruction mission including
stockpiled weapons and recovered
chemical weapons; (4) addresses
environmental health emerging hazards
by conducting surveillance, public
health response, and environmental
epidemiologic investigations and
studies; (5) responds to outbreak or
cluster investigations of non-infectious
etiology; and (6) builds the
environmental epidemiology capacity of
domestic and international public
health partners.
Environmental Public Health
Tracking Branch (CNCG) (1) develops
and maintains the National
Environmental Public Health Tracking
Network, the cornerstone of the
Environmental Public Health Tracking
Program, which connects environmental
and health data at the national, state,
and local levels to drive innovative,
cutting-edge programs and solutions
that protect and improve the health of
communities across the country; (2)
collects, integrates, analyzes, and
disseminates non-infectious disease,
environmental, and sociodemographic
data from a collective of partners at the
national, state, and local levels; (3)
delivers health, exposure, and hazards
data, information summaries, and tools
to enable analysis, visualization, and
reporting of insights drawn from data;
(4) provides timely, local, accessible
information that drives actions to
improve community health; and (5)
empowers environmental and public
health practitioners, healthcare
providers, community members, policy
makers, and others to make informationdriven decisions that affect their health.
Delegations of Authority
All delegations and redelegations of
authority made to officials and
employees of affected organizational
components will continue in them or
their successors pending further
redelegation, provided they are
consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2024–1 Phase I and Phase II: Reagents for
Immunologic Analysis of Non-mammalian
and Underrepresented Mammalian Models
(Topic 129).
Date: February 26–29, 2024.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Poonam Tewary, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761–7219, tewaryp@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01954 Filed 1–31–24; 8:45 am]
Robin Bailey, Jr.,
Chief Operating Officer, Centers for Disease
Control and Prevention.
BILLING CODE 4140–01–P
[FR Doc. 2024–02018 Filed 1–31–24; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00029
Fmt 4703
Sfmt 9990
6527
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 89, Number 22 (Thursday, February 1, 2024)]
[Notices]
[Page 6527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01954]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2024-1 Phase I
and Phase II: Reagents for Immunologic Analysis of Non-mammalian and
Underrepresented Mammalian Models (Topic 129).
Date: February 26-29, 2024.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Poonam Tewary, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761-7219, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01954 Filed 1-31-24; 8:45 am]
BILLING CODE 4140-01-P
